Bridgefront Capital, LLC Exelixis, Inc. Transaction History

Bridgefront Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $29,126 - $33,981	-1,432 Reduced 8.9%	14,658 $329,000
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $136,288 - $161,695	-6,757 Reduced 29.57%	16,090 $381,000
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $231,654 - $290,380	12,034 Added 111.29%	22,847 $548,000
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $205,879 - $245,887	10,813 New	10,813 $236,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.